Clinical Trials

Thoracic

Small Cell Lung Carcinoma

NCT04566393 2026-01-28

Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies

CNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Glioblastoma, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT06910137 2026-01-08

An Early Access Program Guideline to Provide Access to Retifanlimab (INCMGA00012) Together With Carboplatin and Paclitaxel for Squamous Carcinoma of the Anal Canal (SCAC)

Gastrointestinal

Anus Neoplasms, Carcinoma, Squamous Cell

NCT05619367 2025-12-23

A Compassionate Use (CU) Program of Odronextamab

Lymphoma, Follicular, Recurrence, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT04771078 2025-12-12

Expanded Access Protocol (EAP) for Participants Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release

Plasma cell

Multiple Myeloma

NCT04400591 2025-12-11

Nonconforming Lisocabtagene Maraleucel Expanded Access Protocol

Lymphoma, Large B-Cell, Diffuse

NCT03601442 2025-12-05

CTL019 Out of Specification MAP for ALL or DLBCL Patients

LymphoidOther hematologic neoplasm

Recurrence, Lymphoma, Large B-Cell, Diffuse, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04360005 2025-12-05

Managed Access Programs for ABL001, Asciminib

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT05776160 2025-12-01

Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel

Lymphoma, Follicular

NCT04745637 2025-11-18

Managed Access Programs for INC424, Ruxolitinib

Myeloid

Polycythemia Vera, Primary Myelofibrosis

NCT05974410 2025-10-02

Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients

BreastCNSGastrointestinalGenitourinaryGynecologicLymphoidSarcoma

Brain Neoplasms, Breast Neoplasms, Carcinoma, Squamous Cell, Glioblastoma, Hodgkin Disease, Lymphoma, Non-Hodgkin, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms

NCT02632994 2025-09-29

Master Rollover Protocol for Continued Safety Assessment of Study Drug

Neoplasms

NCT06048081 2025-09-10

Early Access Program for Zolbetuximab

Adenocarcinoma

NCT06872489 2025-07-23

Expanded Access Protocol for the Use of SL-28 in the Treatment of Advanced Solid Tumors

CNSGastrointestinalHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Neuroblastoma, Pancreatic Neoplasms, Recurrence

NCT06090331 2025-07-08

89Zr-DFO-girentuximab Expanded Access Program (EAP)

Genitourinary

Carcinoma, Renal Cell

NCT05398640 2025-06-17

Expanded Access Program of AMTAGVI That is Out of Specification for Commercial Release

Dermatologic

Melanoma

NCT06362590 2025-06-17

Expanded Access Use of Ladiratuzumab Vedotin in Advanced Solid Tumors

NCT05650476 2025-06-12

Pre-approval Single-patient Expanded Access for Talazoparib (PF-06944076)

Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT04809233 2025-06-04

Expanded Access to Tipifarnib

Lymphoma, Lymphoma, T-Cell, Peripheral

NCT05738538 2025-06-04

Expanded Access to Ziftomenib

LymphoidOther hematologic neoplasm

Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06980506 2025-05-22

MNPR-101-DFO*-89Zr Expanded Access Program (EAP) for Patients With Solid Tumor Cancer

Neoplasms

NCT06980519 2025-05-22

MNPR-101-PCTA-177Lu Expanded Access Program (EAP) for Patients With Solid Tumor Cancer

Neoplasms

NCT05572970 2025-04-30

Expanded Access for Cancer Treatment With Balstilimab (AGEN2034) and Zalifrelimab (AGEN1884)